(+)-JQ1

Catalog No.S7110

(+)-JQ1 Chemical Structure

Molecular Weight(MW): 456.99

(+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.

Size Price Stock Quantity  
USD 270 In stock
USD 570 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

7 Customer Reviews

  • The BET protein inhibitor JQ1 reduces c-Myc expression and attenuates primary MCC cell proliferation. A, decreased c-Myc expression in MCC-3 and MCC-5 treated with JQ1 (800 nmol/L) for 72 hours by qRT-PCR and immunoblotting. The mRNA expression of target genes was normalized to that of MRPS2 and a value of 1.0 was assigned to the mRNA expression of target genes in the control group (means+SEM; **, P < 0.01 vs. control); b-actin was used as a loading control for immunoblotting.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

    Immunohistochemical staining of xenograft tumor tissues. Immunohistochemical staining of xenograft tumor tissues with the indicated antibodies. p21-, p27-, p57-, and Ki67 positive cells (brown staining) were quantified at x400 magnification (meansSEM;**, P < 0.01;***, P < 0.001 vs. control); scale bars, 10 um.

    Cancer Res 2014 74(23), 7090-102. (+)-JQ1 purchased from Selleck.

  • (D) Effect of JQ1 on alterations of actin cytoskeleton in VEGF-induced HUVECs. The cells were pretreated with DMSO or JQ1 (100 nM) for 6 h, and stimulated with VEGF (10 ng/mL) for 12 h. F-actin (red) and nuclei (blue) were stained with phalloidin and DAPI, respectively. Representative images from 3 independent experiments.

    Sci Rep, 2016, 6:23770.. (+)-JQ1 purchased from Selleck.

    Sensitivity of BEZ235-resistant cells to JQ-1 using the MTT assay.

    Oncotarget, 2016, 6(7):5134-46.. (+)-JQ1 purchased from Selleck.

  • B. Repressed MCC-3 xenograft tumor growth upon combined treatment with MLN0128 and JQ1. Tumor bearing mice were treated with MLN0128 or vehicle at 1 mg/kg/day by oral gavage and JQ1 or vehicle at 50 mg/kg/day by i.p. injection for a period of 30 days. C. A more effective reduction of MCC-3 xenograft tumor growth in the group treated with combined therapy. Fold-reduction of tumor growth was calculated as average tumor growth of control group divided by average tumor growth of treatment group. Tumor growth was calculated as final average tumor volume minus initial average tumor volume in each group.

    Oncotarget, 2016, 7(6):6576-92.. (+)-JQ1 purchased from Selleck.

    JQ1 induces cell cycle arrest and apoptosis in Cal27 cells. (C) Cal27 cells were treated with JQ1 for 24 h and whole cell lysates were tested by western blot assays for the expression of cleaved-caspase-3. GAPDH was used as a loading control. (D) Apoptosis of Cal27 cells treated with JQ1 at 0 and 0.5 µM JQ1; *P<0.05 vs. control (the DMSO group)

    Oncol Rep, 2016, 36(4):1989-96.. (+)-JQ1 purchased from Selleck.

  • Effect of BET domain family inhibition on AMI damage in cardiomyocytes. (A) LDH and (B) CK-MB activity in the serum. #P<0.01 vs. sham group; @P<0.05 and &P<0.01 vs. AMI group. BET, bromodomain and extra-terminal; AMI, acute myocardial infarction; LDH, lactate dehydrogenase; CK-MB, creatine kinase MB isoenzyme.

    Exp Ther Med, 2015, 10(6):2319-2324.. (+)-JQ1 purchased from Selleck.

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description (+)-JQ1 is a BET bromodomain inhibitor, with IC50 of 77 nM/33 nM for BRD4(1/2) in cell-free assays, binding to all bromodomains of the BET family, but not to bromodomains outside the BET family.
Features (+)-JQ1 is more effective than (-)-JQ1.
Targets
BRD4 (2) [1]
(Cell-free assay)
BRD4 (1) [1]
(Cell-free assay)
33 nM 77 nM
In vitro

(+)-JQ1 enantiomer binds directly into the Kac binding site of BET bromodomains. (+)-JQ1 (500 nM) binds BRD4 competitively with chromatin resulting in differentiation and growth arrest of NMC cells. (+)-JQ1 (500 nM) attenuates rapid proliferation of NMC 797 and Per403 cell lines as demonstrated by reduced Ki67 staining. (+)-JQ1 (500 nM) potently decreases expression of both BRD4 target genes in NMC 797 cells. (+)-JQ1 inhibits cellular viability with IC50 of 4 nM in NMC 11060 cells. [1] (+)-JQ1 results in robust inhibition of MYC expression in MM cell lines. (+)-JQ1 inhibits proliferating of KMS-34 and LR5 with IC50 of 68 nM and 98 nM, respectively. (+)-JQ1 (500 nM)-treated MM.1S cells results in a pronounced decrease in the proportion of cells in S-phase, with a concomitant increase in cells arrested in G0/G1. (+)-JQ1 (500 nM) results in pronounced cellular senescence by beta-galactosidase staining. (+)-JQ1 (800 nM) exposure leads to a significant reduction in cell viability among the majority of CD138+ patient-derived MM samples tested. [2] (+)-JQ1 inhibits growth of LP-1 cells with GI50 of 98 nM. (+)-JQ1 (625 nM) results in an increase in the percentage of LP-1 cells in G0/G1. (+)-JQ1 (500 nM) suppresses the expression of MYC, BRD4 and CDK9 in LP-1 cells. [3] (+)-JQ1 (1 μM) activates HIV transcription in latently infected Jurkat T cells. (+)-JQ1 (50 μM) stimulates predominantly Tat-dependent HIV transcription in both Jurkat and HeLa cells. (+)-JQ1 (5 μM) induces Brd4 dissociation enables Tat to recruit SEC to HIV promoter and induce Pol II CTD phosphorylation and viral transcription in J-Lat A2 cells. JQ1 enables Tat to increase CDK9 T-loop phosphorylation and partially dissociates P-TEFb from 7SK snRNP in Jurkat T cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
K1  NWnaUHFiS2WubDDWbYFjcWyrdImgRZN{[Xl? MVGyOVAwPTByL{GwNFAhdk1? M3faNlI1NzR6L{eyJIg> NIrL[2RFVVOR NEDMbGFqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz M4HycVI3PzB5OEix
BCPAP NX;ud3k3S2WubDDWbYFjcWyrdImgRZN{[Xl? NGr1ZlYzPTBxNUCwM|ExODBibl2= MonMNlQwPDhxN{KgbC=> M4f6SWROW09? NYXNXJJQcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDDkc5NmNSCjbnSgeIlu\S1iZHXw[Y5l\W62IH3hco5meg>? NGPFN3gzPjdyN{i4NS=>
K1  M{GyRWNmdGxiQ4njcIUhSXO|YYm= NGPRdWczPTBxNUCwM|ExODBibl2= NIDm[WI4OiCq MnjxSG1UVw>? MoTBZZJz\XO2czDj[YxtKGO7Y3zlJIF1KEdyL1exJJBp[XOn NV3IRXV[OjZ5MEe4PFE>
BCPAP NHu0ZlNE\WyuIFP5Z4xmKEG|c3H5 M3i2PVI2OC93MECvNVAxOCCwTR?= M1u2eVczKGh? MoLGSG1UVw>? NYWyN3J3[XK{ZYP0d{Bk\WyuIHP5Z4xmKGG2IFewM2cyKHCqYYPl MYCyOlcxPzh6MR?=
Hep3B M4Hh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWiwMVExKM7:TR?= MUm1JIQ> Ml7MSG1UVw>? MVjJR|UxRTBwMEig{txO MoWyNlY2PzVzNke=
HCCLM3 NEPTN2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfXNE0yOCEQvF2= NWXjOYhWPSCm M3\FV2ROW09? NXj4c5BXUUN3ME2wMlE1KM7:TR?= Mn\RNlY2PzVzNke=
HuH7 M1jM[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HpO|AuOTBizszN NHnVPY02KGR? Mnq5SG1UVw>? NFW0d4FKSzVyPUCuNlEh|ryP NGfz[YkzPjV5NUG2Oy=>
HepG2 M1XpTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7wUXd[OC1zMDFOwG0> NITuWog2KGR? NUDoV3JJTE2VTx?= MmrSTWM2OD1yLkO0JO69VQ>? M3y0W|I3PTd3MU[3
SMMC7721 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWSwMVExKM7:TR?= NITXbpE2KGR? MlPKSG1UVw>? NVO3Om1mUUN3ME2wMlQyKM7:TR?= NXH5fll[OjZ3N{WxOlc>
BEL7402 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmHENE0yOCEQvF2= Mm[yOUBl NI[5dI5FVVOR NFiyfJhKSzVyPUCuOFch|ryP NFLKXHUzPjV5NUG2Oy=>
MHCC97H NYLnV29bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jDc|AuOTBizszN M2n1cFUh\A>? MUXEUXNQ NHTtTGFKSzVyPUCuOFEh|ryP MVGyOlU4PTF4Nx?=
Hep3B M3j0XGNmdGxiQ4njcIUhSXO|YYm= NFPDb40xNjFxMD61M|IvPSEQvF2= M4rTUlQ5KGh? NUXTWoNKTE2VTx?= NHHYbHht\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iCKQ1OgZ4VtdHNiaX6gd5VjNUdzIIDoZZNmyqB? NVHoco1FOjZ3N{WxOlc>
HCCLM3 NWXOeJRqS2WubDDDfYNt\SCDc4PhfS=> NH25UIwxNjFxMD61M|IvPSEQvF2= NWr0UXpxPDhiaB?= NEDYfVBFVVOR MULs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kBJS0NiY3XscJMhcW5ic4XiMWcyKHCqYYPlxsA> MkGwNlY2PzVzNke=
Hep3B Mk\FRZBweHSxc3nzJGF{e2G7 NUXIRYVXOC5zL{CuOU8zNjVizszN NW\SV|BXPDhiaB?= NFzEXnJFVVOR M3XENIFkfGm4YYTld{Bk[XOyYYPlMVMh[W6mIHPhd5Bie2VvOTDlfJBz\XO|aX;uJIFv\CCrbnT1Z4VlKFCDUmCgZ4xm[X[jZ3WgZZMhf2WubDDhd{BkgXSxY3jyc41mKGNicnXs[YF{\SCrboTvJJRp\SCleYTvdIxie21iZoLvcUBucXSxY3jvcoRzcWF? NVfFUoJlOjZ3N{WxOlc>
HCCLM3 NFzWeHZCeG:ydH;zbZMhSXO|YYm= NFm1[|YxNjFxMD61M|IvPSEQvF2= MXy0PEBp NHvkd4JFVVOR NWHiTHd7[WO2aY\heIV{KGOjc4Dhd4UuOyCjbnSgZ4F{eGG|ZT25JIV5eHKnc4Ppc44h[W6mIHnu[JVk\WRiUFHSVEBkdGWjdnHn[UBieyC5ZXzsJIF{KGO7dH;jbJJwdWViYzDy[Yxm[XOnIHnueI8hfGinIHP5eI9xdGG|bTDmdo9uKG2rdH;jbI9v\HKrYR?= M{KwSlI3PTd3MU[3
A549 NFnZ[HRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XJSVAvOS1zMDFOwG0> NIDpXYg4OiCq NGfj[4JqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? NHfNcVYzPjRzNUKyOS=>
H157 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVGwMlEuOTBizszN M3HSPVczKGh? NGTiUZNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MUeyOlQyPTJ{NR?=
H1299 NF;pSYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LMcVAvOS1zMDFOwG0> MkT6O|IhcA>? NWGxdIRXcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NXHOc5ZMOjZ2MUWyNlU>
A549 MXLGeY5kfGmxbjDBd5NigQ>? NHnjdY0yNzJwNT:1JO69VQ>? MoTsNVIhcA>? NELUXVjDqHenYXvsfUBl\WO{ZXHz[YQhSmOuLUKgcIV3\Wy| NH\QeFUzPjRzNUKyOS=>
H1299 M1vOZmZ2dmO2aX;uJGF{e2G7 MlXDNU8zNjVxNTFOwG0> NYPnTm4xOTJiaB?= MnmwxsB4\WGtbImg[IVkemWjc3XkJGJkdC1{IHzleoVtew>? NVu4d4tHOjZ2MUWyNlU>
H157 Ml3xSpVv[3Srb36gRZN{[Xl? NX7Fb5prOS9{LkWvOUDPxE1? NWe3dWRpOTJiaB?= NF3ZNZhl\WO{ZXHz[YQhTFJ2IHX4dJJme3Orb36= MViyOlQyPTJ{NR?=
H1299 MoXGSpVv[3Srb36gRZN{[Xl? NEnieocyNzJwNT:1JO69VQ>? NVjETGg{OTJiaB?= MVfk[YNz\WG|ZXSgSHI1KGW6cILld5Nqd25? MXOyOlQyPTJ{NR?=
C8161 NILhNJFE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MWewMVIh|ryP Ml;POEBl M3XZTGROW09? Mlzr[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M3T6T|I3Ozl5MkKz
Mel285 NHviN41E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnHqNE0zKM7:TR?= MljoOEBl MmLsSG1UVw>? NIXyXXJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MoT0NlY{QTd{MkO=
Mel290 M1jX[WNmdGxiVnnhZoltcXS7IFHzd4F6 MmX1NE0zKM7:TR?= M1yyWVQh\A>? Mk\3SG1UVw>? Ml;O[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NF7Nc|gzPjN7N{KyNy=>
92.1 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3r5eVAuOiEQvF2= MWK0JIQ> NXrqPYk6TE2VTx?= MUjk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NY\k[Wc2OjZ|OUeyNlM>
Omm1.3 NEe1cYJE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NF31U2UxNTJizszN M{fa[|Qh\A>? M1\DOGROW09? MVrk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? Ml32NlY{QTd{MkO=
Mel202 MYPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MkPjNE0zKM7:TR?= NIKzUpI1KGR? NX;HS4UyTE2VTx?= M3z5dIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NUTHO3F4OjZ|OUeyNlM>
Mel270 NFfVXXVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NYnGfHJWOC1{IN88US=> MnPkOEBl NWL6dpBqTE2VTx?= NXfFSoc4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3XSc|I3Ozl5MkKz
Omm1 MXHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1zGTVAuOiEQvF2= Mn;0OEBl MUfEUXNQ Mn73[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M4DBPVI3Ozl5MkKz
92.1 M{fZVGFxd3C2b4Ppd{BCe3OjeR?= NGHaU|Y2ODBibl2= Ml3FOFghcA>? M3HIZmROW09? NXm0SY9kcW6mdXPld{BieG:ydH;zbZM> NEjBfZEzPjN7N{KyNy=>
Omm1.3 MmizRZBweHSxc3nzJGF{e2G7 MWC1NFAhdk1? NIHHZpI1QCCq NUCzc3A3TE2VTx?= NHn6VIpqdmS3Y3XzJIFxd3C2b4Ppdy=> MXSyOlM6PzJ{Mx?=
92.1 MV\D[YxtKEO7Y3zlJGF{e2G7 M{nLfVUxOCCwTR?= NWTuNoxtOjRxNEivO|IhcA>? NHftUoVFVVOR MWHpcoR2[2W|IITo[UBk\WyuIHHjZ5VufWyjdHnvckBifCC|dXKtS|HDqA>? NEXRdJozPjN7N{KyNy=>
Omm1.3 NFi1UHhE\WyuIFP5Z4xmKEG|c3H5 M2rFOFUxOCCwTR?= NEjkS2gzPC92OD:3NkBp NFzIR2pFVVOR NEjNcHNqdmS3Y3XzJJRp\SClZXzsJIFk[3WvdXzheIlwdiCjdDDzeYIuTzIEoB?= MVmyOlM6PzJ{Mx?=
A549 MYDGeY5kfGmxbjDBd5NigQ>? NV35fXg6OTByL{SwNE8yODByIH7N M33GVlI1KGh? NVHjOFJpfXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NEDSNVgzPjJzMkG5PS=>
MCF-7 MVzGeY5kfGmxbjDBd5NigQ>? MUSxNFAwPDByL{GwNFAhdk1? MW[yOEBp NXTHboY1fXC{ZXf1cIF1\XNiYX7kJIFkfGm4YYTld{BUUVKWMR?= NXXzZodLOjZ{MUKxPVk>
HEK293 MVfGeY5kfGmxbjDBd5NigQ>? M2[yZVExOC92MECvNVAxOCCwTR?= M3X0XVI1KGh? M2Xj[5VxemWpdXzheIV{KGGwZDDhZ5RqfmG2ZYOgV2lTXDF? M3nBWVI3OjF{MUm5
858 M3zMbmNmdGxiVnnhZoltcXS7IFHzd4F6 MonINE0yKM7:TR?= NEj0W4g2KGR? NX;4bpV7TE2VTx?= M2\xSYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NWDSWGU3OjZ{ME[zN|M>
DDR2L63V MlPaR4VtdCCYaXHibYxqfHliQYPzZZk> NILjR44xNTFizszN MnzTOUBl M4fkVmROW09? M3vxZ4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NYSzVYw1OjZ{ME[zN|M>
BE(2)-C Mlm5R4VtdCCYaXHibYxqfHliQYPzZZk> NEe5cI8yKM7:TR?= MXKxMVQh\A>? Moji[IVkemWjc3XzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk> MkjLNlYxPjd2NkS=
IMR-32 M{XleWNmdGxiVnnhZoltcXS7IFHzd4F6 NXTFfohQOSEQvF2= MXSxMVQh\A>? NGLj[JVl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? MV2yOlA3PzR4NB?=
JF MoLUR4VtdCCYaXHibYxqfHliQYPzZZk> M3PiWFEh|ryP MoDMNU01KGR? NEPG[|Bl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NFT3XJUzPjB4N{S2OC=>
BE(2)-M17 NUjp[WhwS2WubDDWbYFjcWyrdImgRZN{[Xl? M3HZeVEh|ryP M3\ueVEuPCCm M{ntW4Rm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDzbYdvcW[rY3HueIx6 MUWyOlA3PzR4NB?=
SK-N-SH MYXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M370[|Eh|ryP M{HJbVEuPCCm NVvm[npC\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JJNq\26rZnnjZY51dHl? NH7mWJozPjB4N{S2OC=>
SK-N-DZ  NX3kVXpSS2WubDDWbYFjcWyrdImgRZN{[Xl? MUKxJO69VQ>? NXeyenBWOS12IHS= NFfFTItl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgd4lodmmoaXPhcpRtgQ>? NFPnUIUzPjB4N{S2OC=>
HMC-1.1  Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ftSlUuPTByMDDuUS=> NUjsWI03PDhiaB?= NGTmSmlFVVOR MoHtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> Mln5NlYxPTV|MEO=
HMC-1.2 MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrmb5E2NTVyMECgcm0> MX20PEBp NH;yc4dFVVOR MlXXbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MlfuNlYxPTV|MEO=
ROSA KIT WT  MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LTN|UuPTByMDDuUS=> MnXLOFghcA>? MknwSG1UVw>? M4LvbolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NUnM[WJLOjZyNUWzNFM>
ROSA KIT D816V M4PCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfNO|c2NTVyMECgcm0> NYrFe3FwPDhiaB?= MUDEUXNQ Ml7HbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MkLtNlYxPTV|MEO=
HMC-1.1  NGLUe4lCeG:ydH;zbZMhSXO|YYm= NIe3bHQzODBvNUCwNEBvVQ>? MYK0PEBp M1nDXGROW09? NFKyNFNqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NGjmc|YzPjB3NUOwNy=>
HMC-1.2 MmH1RZBweHSxc3nzJGF{e2G7 NXf2d2pwOjByLUWwNFAhdk1? MVW0PEBp M{\obGROW09? NF:3ToxqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NEn1XWYzPjB3NUOwNy=>
ROSA KIT WT  MX7BdI9xfG:|aYOgRZN{[Xl? MVuyNFAuPTByMDDuUS=> M2j2T|Q5KGh? M33yd2ROW09? NEK0eo5qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NF:xNZczPjB3NUOwNy=>
ROSA KIT D816V MlOyRZBweHSxc3nzJGF{e2G7 MX6yNFAuPTByMDDuUS=> MnTYOFghcA>? NEnsRW9FVVOR Mn:4bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mnf0NlYxPTV|MEO=
494H MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYGx[IdqPzJiaB?= MV\EUXNQ MULJR|UxRTBwMUKyxtExNjByNDFOwG0> MlO2NlU6PDR3Nk[=
493H NV;QdWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYO3NkBp Mor3SG1UVw>? M3\GNGlEPTB;MD6wOFfDuTBwMEC5JO69VQ>? MWCyOVk1PDV4Nh?=
716H NGPZSYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGP1[pQ4OiCq NGDyVZJFVVOR MXnJR|UxRTBwMkGyxtExNjB|NDFOwG0> MXqyOVk1PDV4Nh?=
148I M13ZPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nm[lczKGh? MoixSG1UVw>? MVrJR|UxRTBwMki0xtExNjB|NTFOwG0> M2nnb|I2QTR2NU[2
98Sc M3fZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICxSXA4OiCq NEHaU4pFVVOR MXfJR|UxRTBwMUG1xtExNjByNDFOwG0> NVTWPJNnOjV7NES1OlY>
89R NVH3N|llT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGi0bVI4OiCq MkTTSG1UVw>? NITTXnpKSzVyPUCuNVI3yrFyLkCwN{DPxE1? NHrYfVIzPTl2NEW2Oi=>
494L MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYe3NkBp MnfNSG1UVw>? MYfJR|UxRTBwM{G3xtExNjBzMjFOwG0> NHXxZnkzPTl2NEW2Oi=>
493L MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUe3NkBp NIjpUJpFVVOR MWHJR|UxRTBwMEWwxtExNjBzMTFOwG0> MkfGNlU6PDR3Nk[=
148L NXnpUolxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVG3NkBp NHXFfFJFVVOR M1HSSGlEPTB;MD6xOFbDuTBwMEG3JO69VQ>? MYGyOVk1PDV4Nh?=
98L NIDSU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLZZmhoPzJiaB?= MmS3SG1UVw>? NE\1TYlKSzVyPUCuN|A6yrFyLkCyPUDPxE1? NYLLcolOOjV7NES1OlY>
OS17 NFL3SodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PQc|czKGh? NU\KV5dXTE2VTx?= MnfJTWM2OD1yLkC3PeKyOC5yMEOg{txO NGri[2IzPTl2NEW2Oi=>
OS9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LXflczKGh? NH;FT|VFVVOR MWDJR|UxRTBwNEC2xtExNjB{ODFOwG0> Mn7FNlU6PDR3Nk[=
MG63 M3XPcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDQNJA4OiCq NYn2WYpsTE2VTx?= MnrpTWM2OD1yLkGxOOKyOC5yMkWg{txO MXqyOVk1PDV4Nh?=
SAOS2 M2HKVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\3O|IhcA>? M{S5dmROW09? M4Lp[GlEPTB;MD6yNVfDuTBwMECzJO69VQ>? NEfNS2czPTl2NEW2Oi=>
U2OS M1rZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYO3NkBp NV\4cWZYTE2VTx?= NHP0fYtKSzVyPUCuNVk5yrFyLkCwPEDPxE1? NIf0R4UzPTl2NEW2Oi=>
SJSA-1 M2i4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHPSlI4OiCq MVjEUXNQ NFXHVFFKSzVyPUCuNVAxyrFyLkCxNEDPxE1? M2fzW|I2QTR2NU[2
494H M37JPWFxd3C2b4Ppd{BCe3OjeR?= M2\rPVAvOjVxMD61M|EvOCEQvF2= MXiyOEBp NIPoeY5FVVOR NHL3NHZqdmO{ZXHz[ZMhdGW4ZXzzJI9nKGOuZXH2[YQh[2G|cHHz[U0{yqB? MViyOVk1PDV4Nh?=
148I MmD6RZBweHSxc3nzJGF{e2G7 NFznWlkxNjJ3L{CuOU8yNjBizszN MlTONlQhcA>? M{DQR2ROW09? NXWzRVRHcW6lcnXhd4V{KGyndnXsd{Bw\iClbHXheoVlKGOjc4Dhd4UuO8Li NYGzdJdpOjV7NES1OlY>
OS17 MnewRZBweHSxc3nzJGF{e2G7 NVXzTXh6OC5{NT:wMlUwOS5yIN88US=> MnvHNlQhcA>? MnTDSG1UVw>? Mk\mbY5kemWjc3XzJIxmfmWuczDv[kBkdGWjdnXkJINie3Cjc3WtN:Kh MViyOVk1PDV4Nh?=
494H MYHBdI9xfG:|aYOgRZN{[Xl? M3\E[|HjiIoQvF2= MoP6OFghcA>? NGXlXYtFVVOR MlzKbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 NGfLNZAzPTl2NEW2Oi=>
148I MVPBdI9xfG:|aYOgRZN{[Xl? MoDBNgKBkc7:TR?= M2e4Z|Q5KGh? NHrS[49FVVOR MoLPbY5lfWOnczDj[YxtKGGyb4D0c5NqeyC|aXfubYZq[2GwdHz5 MWiyOVk1PDV4Nh?=
OS17 NE\vOHdCeG:ydH;zbZMhSXO|YYm= M3TpR|HjiIoQvF2= M4m5cVQ5KGh? NVG4RXNZTE2VTx?= MVjpcoR2[2W|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bIm= NYnxVGsxOjV7NES1OlY>
MOLM13 NV30NJJsSXCxcITvd4l{KEG|c3H5 MWWyOVAhdk1? NXv4U3E{PDhiaB?= MUTEUXNQ M2ja[Ylv\HWlZYOgd4lodmmoaXPhcpRtgSCjcH;weI9{cXNiY3;0doVifG2nboSge4l1cCCzdXn6ZZJ1cW6rYh?= NInseIszPTB3M{iyOS=>
MV4-11  NV\KdXZYSXCxcITvd4l{KEG|c3H5 NFns[YIzPTBibl2= M1P6VFQ5KGh? NFP1e3pFVVOR MWDpcoR2[2W|IIPp[45q\mmlYX70cJkh[XCxcITvd4l{KGOxdILlZZRu\W62IIfpeIgheXWrenHyeIlvcWJ? MoW0NlUxPTN6MkW=
MOLM13 Ml7pSpVv[3Srb36gRZN{[Xl? MWOyOVAhdk1? MVSyOEBp MUHEUXNQ MYXlcohidmOnczDxeYl7[XK2aX7pZk1qdmS3Y3XkJI1wemVicEKxMEBDUU1uIHHu[EBkdGWjdnXkJHBCWlB? MVeyOVA2Ozh{NR?=
MV4-11  MlPhSpVv[3Srb36gRZN{[Xl? MVmyOVAhdk1? NH62eGIzPCCq Ml62SG1UVw>? MoXi[Y5p[W6lZYOgdZVqgmG{dHnubYIucW6mdXPl[EBud3KnIICyNUwhSkmPLDDhcoQh[2ynYY\l[EBRSVKS NGPuPYkzPTB3M{iyOS=>
MOLM13 M{CzSmFxd3C2b4Ppd{BCe3OjeR?= NFPIc40zPTBibl2= M1LJXVQ5KGh? NGPpRmlFVVOR NIq2PWxqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk Mn\3NlUxPTN6MkW=
MV4-11  NEKyTYJCeG:ydH;zbZMhSXO|YYm= M2PpVFI2OCCwTR?= NXLoWG1lPDhiaB?= NGDJfXlFVVOR NEfufmVqdmS3Y3XzJJNq\26rZnnjZY51dHliYYDvdJRwe2m|IHPveJJm[XSvZX70JJdqfGhicH;uZZRqdmmk NUDJcZBbOjVyNUO4NlU>
Hela MXXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NXTCeVRLOC13MECgcm0> MoixO|IhcA>? MmK0SG1UVw>? M{L0SIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MUWyOVAxQTJ7NR?=
HBL-1 NYPjc3J7S2WubDDWbYFjcWyrdImgRZN{[Xl? NWjXZZZCOC13MECgcm0> NH\QTIU4OiCq NXHKUVF2TE2VTx?= M2C0RYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NVXheplbOjVyMEmyPVU>
HLY-1 M2[5dWNmdGxiVnnhZoltcXS7IFHzd4F6 M{T2bFAuPTByIH7N NIjnR284OiCq Ml\qSG1UVw>? Mniw[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NXLK[pRXOjVyMEmyPVU>
OCI-Ly3 NYXsO|JwS2WubDDWbYFjcWyrdImgRZN{[Xl? NXrBVJBSOC13MECgcm0> NVT6TIg1PzJiaB?= MnTOSG1UVw>? MYLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MViyOVAxQTJ7NR?=
OCI-Ly10 Mn6zR4VtdCCYaXHibYxqfHliQYPzZZk> NIXCOowxNTVyMDDuUS=> MlXBO|IhcA>? M{mwNmROW09? NUC3XY5E\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MVmyOVAxQTJ7NR?=
SU-DHL-4 MonnR4VtdCCYaXHibYxqfHliQYPzZZk> MoTJNE02ODBibl2= NHnIT|E4OiCq NXfVT|VlTE2VTx?= MkjP[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ M1rMTFI2ODB7Mkm1
SU-DHL-5 MmPvR4VtdCCYaXHibYxqfHliQYPzZZk> M17UUlAuPTByIH7N MYG3NkBp NWH3Zo05TE2VTx?= NGDnT2dl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= NFrJNmczPTByOUK5OS=>
SU-DHL-6 MYDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnHvNE02ODBibl2= NFfmdnk4OiCq MWrEUXNQ NVj1Zlk4\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M3KyTVI2ODB7Mkm1
SU-DHL-10 M1nVVmNmdGxiVnnhZoltcXS7IFHzd4F6 NV;P[XM5OC13MECgcm0> NI\MNHk4OiCq Mn3xSG1UVw>? MVLk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NUDLOlNMOjVyMEmyPVU>
RC-K8 NXGwbXBUS2WubDDWbYFjcWyrdImgRZN{[Xl? MkiwNE02ODBibl2= MYm3NkBp NVP6OGE4TE2VTx?= MnTv[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MmTwNlUxODl{OUW=
OCI-Ly8 NV7BNJhtS2WubDDWbYFjcWyrdImgRZN{[Xl? M4XOUVAuPTByIH7N NH7jNoc4OiCq MnHmSG1UVw>? Monx[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUPzc3BrOjVyMEmyPVU>
OCL-Ly18 NGf3RVBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MVewMVUxOCCwTR?= MnnVO|IhcA>? MVfEUXNQ M2\5coRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M{TpcVI2ODB7Mkm1
OCI-Ly3 NHrPe|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnsS5YyPzJxMkWwM|UxOCCwTR?= MlnuNk84KGR? M4GyR2ROW09? NGX3[ZZqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg MnfuNlUxODl{OUW=
OCI-Ly8 NWHIXWJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnT1NVczNzJ3MD:1NFAhdk1? NHPGSpgzNzdiZB?= NX;2OGp3TE2VTx?= M136OIlv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= NUjnNZg4OjVyMEmyPVU>
SU-DHL-4 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3iwZVE4Oi9{NUCvOVAxKG6P MlruNk84KGR? NFrQRXNFVVOR M1fKfolv\HWlZYOgZ4VtdC2leXPs[UBienKnc4SgZZQhe3WkLVexJJdqfGhibXnubY1idCClZXzsJIRm[XSqwrC= MUGyOVAxQTJ7NR?=
SU-DHL-10 NEHkOldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3NTYsyPzJxMkWwM|UxOCCwTR?= M3zS[lIwPyCm MoXxSG1UVw>? NIfKdItqdmS3Y3XzJINmdGxvY4njcIUh[XK{ZYP0JIF1KHO3Yj3HNUB4cXSqIH3pcolu[WxiY3XscEBl\WG2aNMg NV3ndnBzOjVyMEmyPVU>
OCI-Ly3 NYHaUYpESXCxcITvd4l{KEG|c3H5 M3zUXFE4Oi9{NUCgcm0> MWW3[C=> MmTYSG1UVw>? Mn74bY5kemWjc3XzJINie3Cjc3WtN{84KGGldHn2bZR6yqC|aXfubYZq[2GwdHz5 MWqyOVAxQTJ7NR?=
OCI-Ly8 Mmn2RZBweHSxc3nzJGF{e2G7 NYfmT2RDOTd{L{K1NEBvVQ>? NFrmO3I4\A>? Ml\oSG1UVw>? NHT5OHJqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> M4W0bVI2ODB7Mkm1
SU-DHL-4 MXTBdI9xfG:|aYOgRZN{[Xl? Mn\HNVczNzJ3MDDuUS=> M1rYcVdl NWDXTId5TE2VTx?= NULUO3BNcW6lcnXhd4V{KGOjc4Dhd4UuOy95IHHjeIl3cXS7wrDzbYdvcW[rY3HueIx6 NEjQWWgzPTByOUK5OS=>
SU-DHL-10 NHf4cVdCeG:ydH;zbZMhSXO|YYm= NY\wOnB3OTd{L{K1NEBvVQ>? NGSwcHQ4\A>? MnPXSG1UVw>? NFr2WlVqdmO{ZXHz[ZMh[2G|cHHz[U0{NzdiYXP0bZZqfHoEoIPp[45q\mmlYX70cJk> NGjQTpUzPTByOUK5OS=>

... Click to View More Cell Line Experimental Data

In vivo (+)-JQ1 (50 mg/kg) inhibits tumors growth in mice with NMC 797 xenografts. (+)-JQ1 (50 mg/kg) results in effacement of NUT nuclear speckles in mice with NMC 797 xenografts, consistent with competitive binding to nuclear chromatin. (+)-JQ1 (50 mg/kg) induces strong (grade 31) keratin expression in NMC 797 xenografts. (+)-JQ1 (50 mg/kg) promotes differentiation, tumor regression and prolonged survival in mice models of NMC xenografts. [1] (+)-JQ1 (50 mg/kg) results in a significant prolongation in overall survival of SCID-beige mice orthotopically xenografted after intravenous injection with MM.1S-luc+ cells compared to vehicle-treated animals. [2] (+)-JQ1 (50 mg/kg i.p.) leads to a highly significant increase in survival of mice bearing Raji xenografts. [3]

Protocol

Cell Research:

[1]

+ Expand
  • Cell lines: MC 11060 cells
  • Concentrations: ~500 nM
  • Incubation Time: 48 hours
  • Method:

    Cells are seeded into white, 384-well microtiter plates at 500 cells per well in a total volume of 50 μL media. The 797, TT and TE10 cells are grown in DMEM containing 1% penicillin/streptomycin and 10% FBS. The Per403 cells are grown in DMEM containing 1 % penicillin/streptomycin and 20% FBS. Patient-derived NMC 11060 cells are grown in RPMI with 10% FBS and 1% penicillin/streptomycin. (+)-JQ1 is delivered to microtiter assay plates by robotic pin transfer. Following a 48 hours incubation at 37℃, cells are lysed and wells are assessed for total ATP content using a commercial proliferation assay. Replicate measurements are analyzed with respect to dose and estimates of IC50 are calculated by logistic regression (GraphPad Prism).


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Mice bearing NMC 797 xenografts
  • Formulation: 5% DMSO in 5% dextrose
  • Dosages: 50 mg/kg
  • Administration: intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 91 mg/mL warmed (199.12 mM)
Ethanol 91 mg/mL (199.12 mM)
Water slightly soluble or insoluble
In vivo Add solvents individually and in order:
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 456.99
Formula

C23H25ClN4O2S

CAS No. 1268524-70-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy (+)-JQ1 | (+)-JQ1 supplier | purchase (+)-JQ1 | (+)-JQ1 cost | (+)-JQ1 manufacturer | order (+)-JQ1 | (+)-JQ1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID